2022 Pharmacy Survey Results: Drug Prices | Part 2
Second of six parts
The Inflation Reduction Act that President Joe Biden signed into law on Tuesday includes a provision that will mean the federal government will negotiate prices for Medicare for the first time and another one that puts a $35 limit on monthly out-of-pocket expenses for insulin for Medicare beneficiaries.
Both are major developments in healthcare policy, especially the price negotiation provision.
And both would get a thumbs up from the majority of the respondents to our annual pharmacy survey.
The survey, which was conducted in late June and early July, had over 950 respondents. Our colleagues at Pharmacy Times® helped distribute the survey through their channels.
Most (62%) of the respondents to our survey favored Congress putting a cap on insulin. A slightly smaller proportion (58%) favored CMS negotiating drug prices and 28% were against.
Part of the motivation for Medicare drug negotiation comes from a belief that drug prices are too high, so it was interesting that just over half (54%) of the respondents to our survey indicated that they believe the problem of high drug prices has been exaggerated.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
